Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of IMM-101 in combination with two other drugs, for the treatment of advanced sarcoma, an inoperable leiomyosarcoma or dedifferentiated liposarcoma

Next Previous
Trial Profile

A phase 1/2 study of IMM-101 in combination with two other drugs, for the treatment of advanced sarcoma, an inoperable leiomyosarcoma or dedifferentiated liposarcoma

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics (Primary) ; IMM 101 (Primary)
  • Indications Leiomyosarcoma; Sarcoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 29 May 2020 New trial record
  • 28 May 2020 According to an Immodulon Therapeutics media release, the US FDA has approved the Investigational New Drug (IND) application of this study. The company plans to initiate this study at the centre of excellence in the US. Further details of the study will be announced following the start of the study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top